SPP1 and myeloid sarcoma: These observations suggest that this cytokine may be a therapeutic target to counteract MS progression supporting the finding of Steinman et al. showing that anti-OPN antibodies ameliorate the disease course in experimental autoimmune encephalomyelitis [28].